Dec 02, 2020 / 01:00PM GMT
Christopher Joseph Raymond - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Okay. Let's go ahead and get started. Thanks, everybody, for joining us. My name is Chris Raymond. I'm one of Piper Sandler's biotech analysts. Pleased to have with us our next presenter, which is Regeneron Pharmaceuticals. We have joining us today, Regeneron's CFO, Bob Landry; and also Justin Holko, who is the VP of Investor Relations. So we've got a lot to talk about in this fireside chat format. We have about 25 minutes. So I think what we're going to have Bob do is to provide just some introductory comments, and then we'll dive into questions.
So Bob, please take it away.
Robert E. Landry - Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO
Great, Chris. Good morning. Nice to see you. And good morning, good afternoon to everyone, who's joined us today. Thank you for inviting us to your conference.
So before I begin, let me start with some introductory comments. Let me remind you that today there will be remarks on the
Regeneron Pharmaceuticals Inc at Piper Sandler Healthcare Conference (Virtual) Transcript
Dec 02, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers